Total medical devices industry M&A deals in Q3 2019 worth $8.11bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 45.6% over the previous quarter and a drop of 24.3% when compared with the last four-quarter average, which stood at $10.74bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $7.48bn. At the country level, the US topped the list in terms of deal value at $7.43bn.
In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of M&A deals activity in Q3 2019 was the US with 52 deals, followed by Germany with nine and France with six.
In 2019, as of the end of Q3 2019, medical devices M&A deals worth $31.59bn were announced globally, marking an increase of 39.8% year on year.
Medical devices industry M&A deals in Q3 2019: Top deals
The top five medical devices industry M&A deals accounted for 78.2% of the overall value during Q3 2019.
The combined value of the top five medical devices M&A deals stood at $6.34bn, against the overall value of $8.11bn recorded for the month.
The top five medical devices industry deals of Q3 2019 tracked by GlobalData were:
1) Exact Sciences’ $2.8bn acquisition of Genomic Health
2) The $1.17bn acquisition of BioTek Instruments by Agilent Technologies
3) Siemens Healthineers’ $1.1bn acquisition of Corindus Vascular Robotics
4) The $775m acquisition of Hu-Friedy Manufacturing by Cantel Medical
5) Stryker’s acquisition of GYS Tech and Mobius Imaging for $500m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.